Advanced Non-Squamous and Squamous NSCLC Market set to Register Strong Growth Due to Increased Prevalence of Lung Cancer



The advanced non-squamous and squamous non-small cell lung cancer (NSCLC) market comprises drugs for treating advanced non-squamous and squamous NSCLC. NSCLC accounts for around 85% of all lung cancer cases, with non-squamous and squamous histologies being the most common. Targeted therapies and immune checkpoint inhibitors are replacing chemotherapy as the standard first-line treatment for NSCLC.

The global advanced non-squamous and squamous NSCLC market is estimated to be valued at US$ 10.89 Bn in 2024 and is expected to exhibit a CAGR of 7.0% over the forecast period of 2024-2031.

Key Takeaways

Key players operating in the advanced non-squamous and squamous NSCLC market are AstraZeneca, Roche, Novartis, Pfizer, Bristol-Myers Squibb, Jiangsu Alphamab Biopharmaceuticals, and Jiangsu HengRui Medicine. AstraZeneca's Tagrisso, Roche's Tarceva and Avastin, and Bristol-Myers Squibb's Opdivo are some of the top-selling drugs. The market offers opportunities for biosimilars and pipeline drugs in development. Players are expanding globally with clinical trials and regional partnerships to increase market share.

The key opportunities in the market include emerging immunotherapy combinations, targeted therapies for specific mutations, and biomarker development. Companies are developing drugs with improved safety profiles and expanded indications. The market is also witnessing increased investments from big pharma companies and regional players to develop novel targeted therapies and immunotherapies.

Globally, the market is majorly dominated by North America and Europe. However, Asian countries are expected to provide lucrative expansion opportunities owing to the growing cancer burden, improving access to advanced therapies, and increasing focus of global players on these regions. Players are undertaking various initiatives to expand in Asia Pacific and Latin American countries through regional partnerships and monitoring trials.

Market Drivers

Increased prevalence of lung cancer - Lung cancer incidence and mortality rates continue to rise globally due to significant risk factors like tobacco smoking and air pollution. This extensive patient pool driving the demand for advanced treatment options.

Approvals of novel therapies - The approval of new targeted drugs and immune checkpoint inhibitors as first-line therapies has expanded treatment options beyond chemotherapy. Drugs offering improved efficacy and survival benefits are driving strong revenue growth.

Market Restraints

High cost of therapies - Most advanced targeted therapies and immunotherapies used in NSCLC have list prices ranging from $100,000 per year. This is a major barrier to access in low and middle-income countries.

Resistance to treatments - While new drugs have shown long-term survival benefits, tumor resistance remains a challenge compromising the duration of response over time in most patients.


Segment Analysis
The advanced non-squamous NSCLC segment dominated the market, accounting for over 50% share in 2024. Treatment of advanced non-squamous NSCLC with immunotherapeutic drugs that harness the body's immune system to fight cancer cells has gained significant adoption in recent years. These drugs have shown improved outcomes over chemotherapy for many patients with advanced non-squamous NSCLC.

The squamous cell lung carcinoma segment is the second largest sub-segment. Squamous cell lung cancers tend to grow faster than adenocarcinomas and large cell cancers. Treatment options for advanced squamous NSCLC remain limited compared to non-squamous NSCLC. Therefore drug development specifically targeting squamous lung cancers holds promise.

Global Analysis
North America dominated the global market with a share of over 40% in 2024 owing to high adoption of premium-priced targeted therapies and immunotherapies in the region. However, the Asia Pacific region is anticipated to grow at the fastest pace during the forecast period owing to rapidly growing healthcare infrastructure, rising incidence of lung cancer and increasing focus of global players on emerging Asia Pacific markets. In terms of growth, China and India are expected to offer significant opportunities for market players due to increasing healthcare spending by governments and expansion of healthcare facilities in these countries.

Get more insights on this topic : https://justpaste.it/3e7q8

What Are The Key Data Covered In This Advanced non-squamous and squamous NSCLC  Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Advanced non-squamous and squamous NSCLC 's growth between 2024 and 2031.

:- Accurate calculation of the size of the Advanced non-squamous and squamous NSCLC  and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Advanced non-squamous and squamous NSCLC  Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Advanced non-squamous and squamous NSCLC  vendors

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it

Comments

Post a Comment

Popular posts from this blog

Laser Projection Market is to Witness High Growth Owing to Advancements in RGB Laser Projection Technology

Image
  The laser projection market involves the usage of laser diodes and phosphor wheels to project images instead of traditional light bulbs and rotating color wheels. Laser projection technology offers a variety of benefits over conventional projection including high brightness levels, long lifespan, high resolutions, and high contrast ratios. Laser projectors are increasingly being used for entertainment and commercial applications such as cinemas, digital signage, and conferences & seminars. The demand for   Laser Projection Market is driven by the superior image quality, higher resolutions and brighter images they provide compared to conventional projectors. The laser projection market is estimated to be valued at   USD 17.52 Bn in 2024   and is expected to reach   USD 56.28 Bn by 2031,  growing at a compound annual growth rate  (CAGR) of 18.1% from 2024 to 2031.  Key Takeaways Key players: Key players operating in the laser projection...
Read more

AL Amyloidosis Diagnostics is to Witness High Growth due to Advancements in Molecular Diagnostics and Flow Cytometry

Image
AL amyloidosis, also called primary (AL) amyloidosis, is a plasma cell disorder characterized by the buildup of abnormal protein deposits known as amyloid in tissues and organs. AL amyloidosis can affect the heart, kidneys, liver, nervous system, and digestive system. Early and precise diagnosis of AL Amyloidosis Diagnostics Market is very important for effective treatment and management of the disease. The AL amyloidosis diagnostic market is estimated to be valued at  USD 1.068 billion in 2024   and is expected to reach   USD 1.693 billion by 2031 , growing at a compound annual growth rate   (CAGR) of 6.8% from 2024 to 2031. Key Takeaways Key players operating in the AL amyloidosis diagnostics are Siemens Healthineers, Abbott Laboratories, IMMUNOConcepts, PrognostiX, Ark Diagnostics. The key opportunities in the AL amyloidosis diagnostics market include development of minimally invasive diagnostic techniques, adoption of PET imaging for diagnosis, advanceme...
Read more

Navigating the Stuttering Treatment Market: Top Solutions for Effective Speech Therapy

Image
The stuttering treatment market involves speech therapy techniques that help reduce or eliminate stuttering or stammering symptoms. Stuttering or stammering occurs when the flow of speech is disrupted by involuntary blocking, repetition, or prolongation of certain sounds. Such involuntary disruptions create difficulties in expressing thoughts fluently which can negatively impact an individual's self-confidence and social interactions. The need for effective Stuttering Market treatment solutions is rising due to the availability of advanced methods such as modified fluency shaping techniques, delayed auditory feedback devices, and self-therapy programs. The Global Stuttering Market is estimated to be valued at   USD 51.5 million in 2024   and is expected to reach   USD 150.1 million by 2031 , growing at a compound annual growth rate   (CAGR) of 11.3% from 2024 to 2031. Key Takeaways Key players operating in the stuttering treatment market are Johnson & Johns...
Read more